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Summary
Latent tuberculosis infection (LTBI) is a subclinical infection with Mycobacterium 
(M.) tuberculosis. Children and immunosuppressed individuals due to pathologic condi-
tions or therapeutic procedures are at a high risk of reactivation of LTBI to active disease 
compared to general population and require timely identification. The diagnosis of LTBI 
is based on the measurement an adaptive immune response against M. tuberculosis. The 
use of tuberculin skin test (TST) has been associated with a number of interfering factors 
that cause false-positive or false-negative test results. The new ex vivo whole blood tests 
determining interferon-gamma (IFN-γ) released from T-lymphocytes (interferon-gamma 
release assays, IGRAs) upon stimulation with M. tuberculosis specific antigens.
The introduction of IGRAs to routine clinical practice has improved the diagnosis of 
LTBI, but recommendations and guidelines for the diagnosis of LTBI are not consistent 
between different European countries. Therefore, European centre for disease prevention 
and control developed guidance document based on the up-to-date scientific evidence.
Novel concepts of IGRAs and new studies should be designed so as to provide 
answers to all open questions.
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Reports of the World Health Organisation (WHO) state that approximately one 
third of the world’s population is infected with Mycobacterium (M.) tuberculosis [1]. 
However, a minority of those individuals will ever develop active tuberculosis (TB). 
It is estimated that approximately 5% of immunocompetent infected subjects deve-
lop clinical disease within two years of infection (primary TB), and another 5% over 
their lifetime (post-primary TB or “reactivation”). The remaining 90% of immuno-
competent infected subjects never progress to active disease.
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Latent tuberculosis infection (LTBI) is a state of persistent M. tuberculosis specific 
cell-mediated immune response in the absence of active disease. Although indivi-
duals with LTBI do not manifest clinical symptoms and are not contagious to other, 
they are at increased risk for developing manifest disease. The increased reactivati-
on of LTBI has been observed in immunocompromised situations such as acquired 
or chronic diseases, and therapeutically induced immunodeficiencies.
In the United States and Europe, a significant efficiency in control of TB was 
seen in the 1950s. However, increase of new cases of TB was seen in the 1980s. Al-
though the migration of people from high-prevalence countries is significant epide-
miological factor of TB in developed countries, the most cases of TB in the domestic 
population of the developed countries in the last 30 years occured as result of LTBI 
reactivation.
Therefore, the earliest possible diagnosis of LTBI is a precondition for control 
and potential elimination of TB. Preventive measures for LTBI are considered one 
of the crucial actions in the management of tuberculosis as a public health problem 
worldwide and development of new tools into TB control is one of component of the 
new global Stop TB Strategy [2].
Pathomechanism of tuberculosis infection
Infection with M. tuberculosis starts with phagocytosis of mycobacterium by 
pulmonary dendritic cells. The recognition of the mycobacterium components (19 
and 27 kDa lipoproteins, 38 kDa glycolipoprotein, lipomannan, mannose-capped li-
poarabinomannan) are mediated by many host receptors (Toll-like receptors, C-type 
lectins, nucleotide-binding oligomerization domain-like receptors and the other). 
The interaction of mycobacterium with host receptors initiates an intracellular si-
gnaling cascade that results in a nonspecific proinflammatory response [3]. Dendri-
tic cells migrate to regional lymph node and activate both CD4+ and CD8+ specific 
T lymphocyte. The important characteristic of cell-mediated immune response is 
production of interferon-gamma (IFN-γ), the key cytokine for a immune response 
against M. tuberculosis. IFN-γ induces the transcription of more than 400 genes [4]. 
Their activation contribute to activation of alveolar macrophages, production of ad-
ditional cytokines and induction of additional immune cells, production of effec-
tors such as oxygen radicals and reactive nitrogen intermediates. The granuloma 
formation at the site of infection separates M. tuberculosis from the rest part of the 
lung and controls its replication. TNF-α is another major cytokine for a immune re-
sponse against M. tuberculosis. It stimulates the phagocyte capacity of macrophages 
synergising with IFN-γ. Moreover, TNF-α is also responsible for the granuloma for-
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mation, and is involved in both immune and immunomodulatory responses [5,6]. 
In the majority of infected subjects, an effective cell-mediated immune response 
develops two to eight weeks after infecton with M. tuberculosis. However, the my-
cobacterium is completely removed in approximately only 10% subject, while in 
the remaining individuals the pathogen evades and modulates the host immune 
response. M. tuberculosis responds to the host immne system with transcriptional 
activity of many of its 4000 different genes that may lead to increased survival and 
persistence of the mycobacterium in the host. The early secretory antigenic target 
6 (ESAT-6)/culture filtrate protein 10 (CFP-10) complex is example of M. tuberculosis 
protection mechanism [7]. The complex is secreted by live bacteria and is cruical for 
the virulence of M. tuberculosis. Moreover, ESAT-6/CFP-10 complex disociate at low 
pH (acidification of phagosome in alveolar macrophage), and ESAT-6 inserts itself 
into phagosome lipid bilayer, causing lisis of phagosome and escape M. tuberculosis 
from phagosome. ESAT-6 also induces apoptosis of macrophage by caspase depend-
ent pathway, and causes cytolisis of alveolar epithelial cells causing dispersion of 
M. tuberculosis in extracellular milieu. These mechanisms together with additional 
M. tuberculosis factors may result in the latent infection. The current definition of 
LTBI is based on a dynamic model of infection where endogenous reactivation and 
effective cell-mediated immune response occur constantly in immunocompetent in-
dividuals [8]. On the other hand, if disruption of cell-mediated immunity (depletion 
or functional abnormalities of T lymphocytes, TNF-α absence) occurs the infected 
individuals develop active disease.
ltbi and risk factors
There are two categories of individuals who are risk for tuberculosis infection.
The first group are individuals who are at increased risk for M. tuberculosis in-
fection: direct exposure to tuberculous patient (a member of family, a healthcare 
worker), a foreign-born pearson from high-incidence TB areas and children [9-13]. 
The second group are individuals who are at higher risk of reactivation of LTBI 
to active disease compared to general population or are at higher risk for a poor 
clinical outcome (disseminated and extrapulmonary TB) [14]. It is documented that 
immune suppression is very important predispose factor for progression of LTBI to 
TB (Table 1).
Immunocompromised individuals represents a heterogeneous group which in-
cludes [15]:
• Children (immature immune system) [16]
• Immunodeficiency disorders (human immunodeficiency virus infection, HIV) [17]
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• Chronic disorders (chronic kidney disease, diabetes mellitus) [18,19]
• Immunosuppresion associated with infection or malignancies [20]
• Immunosuppresion associated with therapeutic procedures (organ transplanta-
tion, chemotherapy, TNF-α antagonist, systemic corticosteroids) [21,22]
The most effective way to avoid reactivation of LTBI following immunosuppre-
ssive therapies is early diagnosis and treatment of the LTBI before treatment of the 
main disorder.
Table 1 Risk of LTBI reactivation in immunocompromised subjects
Immunodeficiency Increased risk compared to general population
Disease
HIV 50 - 200
Malignancies 10 - 15
Renal failure 6 - 50
Diabetes mellitus 3
Therapy
TNF-α antagonist > 25
Corticosteroids > 5
Immunosuppressive 20 - 74
HIV; human immunodeficiency virus infection, TNF; tumour necrosis factor
diagnosis of ltbi
The diagnosis of LTBI is based on the measurement an adaptive immune res-
ponse against M. tuberculosis because direct measure of latent infection is not possi-
ble. This response may be measured as delayed type hypersensitivity response by 
the tuberculin skin test (Mantoux test) six to eight weeks after exposure to the M. 
tuberculosis, or as production T lymphocyte cytokine IFN-γ by interferon-gamma 
release assays two to eight weeks after exposure to M. tuberculosis.
For about a century, the diagnosis of tuberculosis infection, of both active and 
latent, was made by use of in vivo tuberculin skin test (TST). The test is based on the 
measurement of delayed hypersensitivity reaction upon intradermal administrati-
on of purified protein derivative (PPD). TST determines the activity of effector and 
memory T-lymphocytes and measures the reaction induced by IFN-γ, interleukin 
(IL) 4, IL 10, IL 12, TNF-α and granulocyte colony-stimulating factor (G-CSF). A si-
gnificant limitation of the TST is heterogeneity of PPD preparation, a poorly defined 
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mixture of more than 200 mycobacterium proteins and protein fragments, including 
antigens from the vaccine strain M. bovis Bacillus Calmette-Guerin (BCG) and from 
non-tuberculosis mycobacteria. Therefore, the test does not differentiate an immune 
responses toward previous BCG vaccination, non-tuberculosis mycobacteria infec-
tion and M. tuberculosis infection [23,24]. Moreover, specificity and sensitivity of the 
TST are diminished by the variable cut off values used on positive TST determinati-
on. As no positive control is used, the test may produce false-negative results due to 
immunosuppressive conditions [25]. However, the TST does not require additional 
infrastructure to be performed.
laboratory diagnosis of ltbi
The diagnosis of tuberculosis infection has been improved with the new ex 
vivo tests which measure antigen specific T lymphocyte function. The basis of this 
tests are effector T lymphocytes in blood of individuals infected with M. tuberculo-
sis which could recognize mycobacterial antigens. Due to the short life of effector 
T lymphocytes, their presence in sample diagnose an ongoing infection. The new 
tests measure IFN-γ released from effector T lymphocytes (interferon-gamma rele-
ase assays, IGRA) upon ex vivo stimulation with specific peptides to M. tuberculosis, 
ESAT-6, CFP-10 and TB7.7 (Rv2654) [26-28]. These peptides are encoded within the 
region of difference (RD) 1 (ESAT-6, CFP-10), and RD 11 (TB7.7) of the M. tuberculosis 
genome and belong to a group of 0.5% of all antigens to this bacterium, thus diffe-
rentiating it from the majority of other mycobacteria (except M. kansasii, M. szulgai, 
M. marinum, M. flavescens, M. gastrii) [29,30].
Up to date, two IGRAs are commercially available,  QuantiFERON-TB Gold In-
Tube (QFT-IT, Cellestis Ltd., Carnegie, Victoria, Australia) and T-SPOT.TB (Oxford 
Immunotec Ltd., Oxford, UK). The primary differences between two IGRAs are the 
sample preparation and the method for detection of IFN-γ production. QFT-IT, an 
enzyme-linked immunosorbent assay, uses whole blood and three specific pepti-
des to M. tuberculosis (ESAT-6, CFP-10, TB7.7 ), and determines IFN-γ concentration. 
T-SPOT.TB, an enzyme-linked immunosorbent spot, uses purified peripheral blood 
mononuclear cells and only two (ESAT-6, CFP-10) specific peptides to M. tuberculosis, 
and determines the percentage IFN-γ releasing lymphocyte.
The very important advantage of IGRAs over TST lies in the possibility of per-
formance quality control. Negative control offers an insight into the nonspecific 
IFN-γ sinthesis or indicates the presence of heterophil antibodies in the sample. 
Positive control determines IFN-γ released from T-cells upon stimulation with the 
mitogen phytohemagglutinin (PHA). Positive control is used to assess the patient’s 
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immune status (lymphocyte count and activity) and preanalytical sample manipu-
lation, thus reducing the rate of false-negative results and increasing the negative 
predictive value of IGRA [31]. A reduced mitogen response, indeterminate result, is 
the uninterpretable result of IGRAs, and whole assay should be repeated in a new 
blood sample [32].
The advantage and disadvantage of IGRAs and TST are sumarized in Table 2.
Table 2 Comparison of interferon-gamma release assays and tuberculin skin test
IGRAs TST
Sample Peripheral blood Skin
Antigen Specific M. tuberculosis antigens
Mixture of mycobacterial 
antigens
Reaction cells Effector T-lymphocytes Effector and memoryT-lymphocytes








None, except M. kansasii,
M. szulgai, M. marinum,
M. flavescens, M. gastrii
May give a false-positive result
„Boosting“ No Yes
False-negative result No, if use positive mitogen control
Possible (immunosuppressed 
subject)
Time to obtain result At least 24 hours At least 48 (72) hours
Subjectivity No Yes
Second visit No Yes
Required equipment Yes No
Distinguish active/latent 
infection No No
IGRA, interferon-gamma release assay; TST, tuberculin skin test
The sensitivity and specificity of IGRAs for diagnosis LTBI can not be reliably 
estimated because there is no gold standard method for the diagnosis of LTBI. The-
refore, the sensitivity has been evaluated in patients with TB and the specificity in 
individuals with no known risk or low-risk factors of tuberculosis infection. In the 
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context of mentioned limitation in assessment of the sensitivity of IGRAs the Euro-
pean centre for disease prevention and control (ECDC) did not assess the sensitivity 
of IGRAs for LTBI diagnosis [33]. The pooled specificity of IGRAs in the diagnosis of 
LTBI was about 99% [34]. Evaluation of positive predictive value (PPV) and negative 
predictive value (NPV) of IGRAs to predict risk for reactivation of LTBI is not possi-
ble at this moment and further studies are indispensable.
The utility of IGRAs varies between different types of immunocompromised 
individuals.
Although the high sensitivity of IGRAs allows for accurate diagnosis of LTBI in 
high risk individuals, indeterminate IGRAs results have been more frequently re-
ported in immunosuppressed subjects [35,36]. Based on the available results, IGRAs 
may be used as part of a combined approach based on IGRAs and TST in order to 
maximise the accuracy of diagnosis in high-risk groups but IGRAs should not be 
used to exclude diagnosis of LTBI in the immunocompromised individuals [37].
Numerous considerations on the application and cost effectiveness of screen-
ing with IGRAs have been published [37-39]. Although they are based on different 
models, their conclusion is corresponded. A dual screening strategy (TST followed 
by IGRAs) or IGRAs alone strategy are more cost effective than TST single screen-
ing. However, this conclusion may be dependent on the population being screened. 
Therefore, each national tuberculose control program should evaluate cost effective-
ness of IGRAs for their own setting. 
Recommendations and guidelines for the diagnosis of LTBI are not consistent 
between different European countries, because there are different TB-incidence 
countries with characteristic TB epidemiology. Therefore, ECDC developed guid-
ance document [33] based on the up-to-date scientific evidence.
In conclusion, the introduction of IGRAs to routine clinical practice has impro-
ved the diagnosis of LTBI. However, still better diagnostic tests are needed. There-
fore, novel concepts of IGRAs and new studies should be designed so as to provide 
answers to all open questions. 
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Latentna tuberkulozna infekcija (LTBI) definira se kao supklinička infekcija bakterijom Myco-
bacterium (M.) tuberculosis. Kod djece i osoba oslabljenog imunološkog sustava, zbog pojedinih 
patoloških stanja ili terapijskih postupaka, postoji veći rizik za aktivaciju LTBI-ja u aktivnu tuber-
kulozu u odnosu na opću populaciju, te je takvu infekciju potrebno pravovremeno otkriti.
Dijagnostika LTBI-ja temelji se na određivanju imunološke reakcije usmjerene protiv M. tu-
berculosis. Primjena tuberkulinskog testa otežana je brojnim čimbenicima koji mogu uzrokovati 
lažno pozitivne i lažno negativne rezultate testa. Novi dijagnostički pristup temelji se na ex vivo 
testovima iz pune krvi kojima se određuje IFN-γ oslobođen iz T-limfocita (interferon-gamma rele-
ase assays, IGRAs) nakon podražaja specifičnim antigenima za M. tuberculosis.
Primjena IGRAs-a u rutinskoj kliničkoj praksi unaprijedila je dijagnostiku LTBI-ja, ali pre-
poruke i smjernice za dijagnostiku LTBI-ja nisu podudarne u pojedinim europskim zemljama. 
Zbog toga je Europski centar za prevenciju bolesti i kontrolu pripremio smjernice utemeljene na 
najnovijim znanstvenim podatcima.
Unaprjeđenja IGRAs-a i nova istraživanja treba kreirati tako da se mogu dati odgovori na 
sva otvorena pitanja.
Ključne riječi: IGRA; latentna tuberkulozna infekcija; tuberkulinski test
